AR and neoplasm: Therefore, castration or the standard AR antagonist treatments, such as bicalutamide and enzalutamide (39), commonly result in the unwanted activation of PI3K/AKT signaling (also see Figure 1D), which may lead to anti-apoptotic activity in PCa cells and thus render tumor cells resistant to the therapies.